VIVO News and Press, Meridian Bioscience Inc. From 12/08/20

Meridian Bioscience ([[VIVO]] -1.0%) has submitted its application for Emergency Use Authorization ((EUA)) to the FDA for its SARS-CoV-2 molecular diagnostic test on the Revogene platform.The molecular diagnostic test is for the qualitative detection of the SARS-CoV-2 virus, with results...

CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administra...

CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecul...

CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Off...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: XLV: Healthcare Dashboard For November

CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuit...

Meridian Bioscience, Inc. (VIVO) Q4 2020 Earnings Conference Call November 13, 2020 10:00 AM ET Company Participants Charlie Wood – Vice President-Investor Relations Jack Kenny – Chief Executive Officer Bryan Baldasare – Chief Financial Officer Conference Call Participant...

Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q4 2020 Earnings Call Nov 13, 2020 , 10:00 a.m. ET Operator Continue reading For further details see: Meridian Bioscience Inc (VIVO) Q4 2020 Earnings Call Transcript

Meridian Bioscience ([[VIVO]] +13.7%) Q4 results:Revenues: $64.2M (+26.0%); Life Science: $34.4M (+97.0%); Diagnostics $29.8M (-11.0%).Net Income: $6.5M (+58.5%); EPS: $0.15 (+50.0%); non-GAAP Net Income: $8.3M (+53.7%); non-GAAP EPS: $0.19 (+46.2%).Cash and equivalents was $53.5M.2021 Guidan...

The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Meridian Bioscience, Inc. 2020 Q4 - Results - Earnings Call Presentation